Loading...
XASX
CMB
Market cap1mUSD
May 07, Last price  
0.01AUD
Name

Regeneus Ltd

Chart & Performance

D1W1MN
XASX:CMB chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-3.53%
Revenues
0k
0998,036920,3531,735,4629,994,064575,40625,0771,663,3457,955,82200
Net income
-2m
L-61.51%
0-7,523,218-6,606,521-3,573,8733,270,592-5,184,600-5,753,820-3,836,3292,153,011-4,382,386-1,686,883
CFO
-660k
L-84.84%
000000000-4,357,426-660,464

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. Its lead platform technology includes Progenza, a multi-synergistic therapy for the treatment of osteoarthritis and neuropathic pain. The company also develops Sygenus for the treatment of skin wound healing. Regeneus Ltd was incorporated in 2007 and is headquartered in Paddington, Australia.
URL
https://regeneus.com.au/
IPO date
Sep 19, 2013
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT